Naperville, IL -- (SBWIRE) -- 10/02/2012 -- Idiopathic (Essential) Hypertension - Pipeline Review, H2 2012, provides an overview of the Idiopathic (Essential) Hypertension therapeutic pipeline. This report provides information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension. 'Idiopathic (Essential) Hypertension - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Idiopathic (Essential) Hypertension.
- A review of the Idiopathic (Essential) Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Idiopathic (Essential) Hypertension pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Idiopathic (Essential) Hypertension therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Idiopathic (Essential) Hypertension Therapeutic Products under Development, Key Players in Idiopathic (Essential) Hypertension Therapeutics, Idiopathic (Essential) Hypertension Pipeline Overview, Idiopathic (Essential) Hypertension Pipeline, Idiopathic (Essential) Hypertension Pipeline Assessment
To view table of contents for this market report please visit:
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)